The Effect of a Ginger Supplement on Digestive Complaints in Healthy Adults Versus a Placebo

NCT ID: NCT06446921

Last Updated: 2024-06-06

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 116 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-06-30
• Study Completion Date: 2025-12-31

Brief Summary

The aim of this clinical study is to investigate the effect of a ginger formulation as a dietary supplement on gastrointestinal complaints in healthy adults.

The effect of this formula will be compared to a placebo after 8 weeks of consumption.

Conditions

Dyspepsia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: QUADRUPLE

Study Groups

Ginger formula

100 mg of ginger formula per capsule 2 capsules per day during 8 weeks

Group Type: EXPERIMENTAL

Ginger formula

Intervention Type: DIETARY_SUPPLEMENT

supplement delivering a minimum of 20 mg of gingeroids / d

Placebo formula

2 capsules per day during 8 weeks

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DIETARY_SUPPLEMENT

arabic gum

Interventions

Ginger formula

supplement delivering a minimum of 20 mg of gingeroids / d

Intervention Type: DIETARY_SUPPLEMENT

Placebo

arabic gum

Intervention Type: DIETARY_SUPPLEMENT

Eligibility Criteria

Inclusion Criteria

• Men and women aged 18-65 years
• Body Mass Index (BMI) 18.5 - 30.0 kg/m2 (limits included)
• Otherwise healthy subjects with Postprandial Distress Syndrome (PDS) as defined by ROME IV criteria: Must include one or both of the following criteria* at least 3 days a week: - Bothersome postprandial fullness (i.e. severe enough to impact on usual activities)
• Bothersome early satiation (i.e. severe enough to prevent finishing a regular size meal)

*Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis with no apparent evidence of organic, systemic or metabolic disease or structural disease by standard clinical examination by the investigator at V0 that is likely to explain the complaints

• Documented Helicobacter pylori negative subjects according to a validated previous test (histological, breath, stool antigen or serological test) in the last 5 years or if not, with a rapid assay realized during V0
• Negative urine pregnancy test for women in childbearing age at V0 At V1, after 1-week diary completion, mean "PDS score" on LPDS scale ≥ 1 and <3 (mild and moderate) As per this randomization criterion, any subjects with a "PDS score" of ≥3 (severe or very severe) or <1 (too low) at V1 will be withdrawn from the study.

For assessment of PDS, the last 7 consecutive days before V1 should be used to calculate the score.

Exclusion Criteria

• Subjects with dominant Epigastric Pain Syndrome (EPS) (as per Rome IV criteria) as main complaints at V0 as per investigator's judgement
• Subject with a dominant Irritable Bowel Syndrome (IBS) as per Rome IV criteria at V0 as per investigator's judgement
• Subjects suffering from or with history of dominant gastroesophageal reflux disease (GERD)-like symptoms at V0 as per investigator's judgement
• Self-reported organic findings in endoscopy in the last 5 years (if any) likely to explain dyspeptic symptoms
• Subject with other chronic gastrointestinal (GI) disorders (e.g. inflammatory bowel disease, coeliac disease)
• History of major gastrointestinal surgery (except for appendectomy or cholecystectomy)
• Suffering from or history of severe chronic disease in the last 5 years (e.g. cancer, HIV, hepatic or biliary disorders ongoing, pancreatic disease, kidney disease, uncontrolled cardiovascular disease, or chronic respiratory diseases) (self-reported)
• Presence of an organic cause explaining the dyspeptic complaints (e.g. peptic ulcer disease or parasitic infection) (self-reported)
• Family history of oesophageal or gastric cancer
• Subjects with diabetes (self-reported)
• Subjects with PHQ-9 (PATIENT HEALTH QUESTIONNAIRE)(score over 15 at V0
• Subjects with GAD-7 (Generalized Anxiety Disorder 7-item) score over 15 at V0
• Active psychiatric conditions (stable dose of 1 antidepressant is allowed, no other medication for psychiatric conditions)
• Subjects under treatment for dyspepsia complaints such as Proton Pump Inhibitors (PPI), Histamine 2 receptor antagonists (H2RAs), prokinetics, within the last 6 weeks before V0 and during the study and not willing to refrain their use during the study
• Subjects under opioids or immunosuppressants (antihistaminics and topical corticosteroids (nasal sprays, cutaneous) are allowed) or Non-steroidal anti-inflammatory drugs (NSAIDS) within the last 2 weeks before V0 and during the study and not willing to refrain their use during the study
• Subjects under treatment of antibiotics within the last 2 months before V0
• Subjects accustomed to use an anti-acid more than 3 times a week and not willing to refrain any consumption of these during the study
• Subjects under treatment of systemic corticoids within the last 3 months before V0 and not willing to refrain their use during the study
• Recent gastroenteritis or food borne illness such as confirmed food poisoning within the last 1 month before V0
• Under dietary supplement or treatment which could significantly affect parameters followed during the study according to the investigator (i.e. with laxative effect, with antidiarrheal effect, containing plant extracts (including ginger extracts), any formulation for digestive health, probiotics, prebiotics, symbiotic, vitamins and minerals) within the last 6 weeks before V0 or not willing to refrain from their consumption during the study
• Subjects used to consume any food and/or drink and/or condiment containing ginger (gari, pickled ginger, Japanese food, tea or infusion…) defined as more than 4 times a week before the study
• Subjects who do not agree to limit any ginger consumption during the study to maximally 4 times a week during the study
• With a known or suspected food allergy or intolerance or hypersensitivity to any of the study products' ingredients and/or for the subgroup (with the gastric emptying test) to any components of the standard meals
• Pregnant or breastfeeding females, or wishing to become pregnant during the study
• With significant change of dietary habits or trying to lose weight within the last 3 months before V0 or planning to change dietary habits during the study or with eating disorders as per investigator judgement
• Following any specific diet such as high-protein, vegan, hypocaloric, ketogenic diet low in FODMAPs (Fructo-, Oligo, Di-Monosaccharides, And Polyols) except for vegetarian which is allowed
• Any change in the physical activity within the last 3 months before V0 or planning to change during the study or participant near or in the peak of training for an athletic race or competition
• Ongoing abuse of drugs, alcohol and / or medication at V0 or history of substance abuse within the last 12 months before V0
• Drinking more than 2 glasses of alcohol per day, every day and without interruption
• Smoking > 10 cigarettes per day
• Heavy caffeinated beverage consumption (>400 mg caffeine/day, i.e. more than 3 mugs of filter coffee or 4 espressos) within the last 2 weeks before V0 and during the study
• Any reason or condition that in the judgment of the clinical investigator(s) may put the subject at unacceptable risk or that may preclude the subject from understanding or complying with the study's requirements
• Participation in any other clinical trial within the last 30 days before V0 and during the study
• Clinically relevant deviations from safety laboratory parameters (see section 11.8.3)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Analyze & Realize

NETWORK

Sponsor Role: collaborator

University Hospital of Leuven Leuven

OTHER

Sponsor Role: collaborator

Givaudan France Naturals

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Tim Vanuytsel, Pr

Role: PRINCIPAL_INVESTIGATOR

UZ Leuven

Central Contacts

Anne Gensch

Role: CONTACT

agensch@a-r.com

49 176 44435206

Geraldine Krausz, phD

Role: CONTACT

geraldine.krausz@givaudan.com

Other Identifiers

GIV/010123

Identifier Type: -

Identifier Source: org_study_id